
Aenduo
Allows the users to share personal health records generated in any context ensuring a unique and integrated customer journey.
Date | Investors | Amount | Round |
---|---|---|---|
* | €420k Valuation: €16.9m 10.6x EV/Revenue | Early VC | |
Total Funding | 000k |
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 23 % | (39 %) | 95 % | 62 % | 81 % | 53 % | 18 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 27 % | 132 % | 108 % | 47 % | 34 % | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 2 % | 73 % | 50 % | 6 % | 11 % | 2 % | 12 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Aenduo S.r.l. is a Rome-based digital health company, founded in 2013 by Massimo Marini and Michelangelo Smeriglio, with Marcello Pediconi currently serving as CEO. The founders possess over two decades of international experience in technology and healthcare, having held managerial roles at companies like Philips Healthcare and successfully executed prior exits in the digital sector with significant multiples. The firm targets the connected health market, focusing on developing medical software technologies for the remote treatment of patients with chronic diseases, particularly within the respiratory therapy sector.
The company's core offering is AdvantCare®, a proprietary, cloud-based software suite certified as a Class IIA medical device. This platform provides healthcare professionals with a holistic view of the patient's entire clinical journey, from diagnosis through follow-up. Its features include remote monitoring of biomedical parameters and therapies, tele-surveillance, remote diagnostics, and virtual consultations. The system is designed to be independent of specific medical device manufacturers and integrates with over 100 different devices, such as those for PAP, BiLevel, ventilation, and oxygen therapy, as well as tools for spirometry, oximetry, and ECGs. By automating workflows and facilitating communication through an app, AdvantCare® aims to reduce administrative burdens for healthcare providers, improve patient outcomes through proactive intervention, and make care more accessible.
Aenduo operates on a B2B model, serving clients like homecare providers, system integrators, and multinational corporations across 8 European countries. Revenue is generated on a recurring basis from the active patients on the platform. The company has demonstrated significant growth, connecting over 160,000 patients and reporting revenues of €1.06 million in 2023. It has secured approximately $560K through an equity crowdfunding campaign and has invested over €1.5 million in R&D, resulting in two industrial invention patents. The company actively collaborates with numerous research institutions, including La Sapienza University of Rome and the University Hospital of Geneva, to maintain its competitive edge.
Keywords: digital health, remote patient monitoring, chronic disease management, respiratory care, HealthTech, medical software, SaaS, telemedicine, AdvantCare, homecare technology, clinical pathway management, biomedical data integration, virtual consultations, medical device interoperability, e-health, remote diagnostics, patient engagement platform, healthcare automation, chronic care, sleep apnea treatment